Navigation Links
QRxPharma Announces Interim Analysis of Final Pivotal Phase 3 Study for MoxDuo®IR
Date:9/1/2010

es relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialisation of the Company's proposed products.

About QRxPharmaQRxPharma (ASX: QRX and OTCQX: QRXPY) is a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management and central nervous system (CNS) disorders. Based on a development strategy which focuses on enhancing and expanding the clinical utility of currently marketed compounds, the Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. The Company intends to co-promote its products in the US and seeks strategic partnerships for worldwide markets. QRxPharma's lead product candidate, MoxDuo IR, is in Phase 3 clinical development and has successfully completed multiple comparative studies evaluating its efficacy and safety against equi-analgesic doses of morphine, oxycodone and Percocet® for the treatment of acute pain. QRxPharma expects to complete its Phase 3 program in Q4 CY2010 and file its New Drug Application (NDA) with the US Food and Drug Administration (FDA) for MoxDuo IR in Q1 CY2011. The Company's preclinical and clinical pipeline includes other technologies in the fields of pain management, neurodegenerative disease and venomics. For more information, visit www.qrxpharma.com.


'/>"/>

SOURCE QRXPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
8. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
9. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
10. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
11. QRxPharma Receives Positive Feedback from Scientific Advice Meetings in Europe on MoxDuo®IR Development and Registration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition ... Analysis, Size, Share, Growth, Trends And Forecast, 2013 - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Dental ... order to treat dental impairments, for tooth restoration and ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)... GARDENS, Fla. , Jan. 15, 2014  In an unprecedented effort ... and TB in ambulances and other transport vehicles, an advanced and ... by rescue personnel for the first time. In ... contact with these deadly pathogens, West Palm Beach ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
(Date:7/9/2014)... Cincinnati, OH, July 10, 2014 -- The World Health ... 60 minutes of moderate to vigorous physical activity (MVPA) ... most of their MVPA during school hours. Therefore, ... school hours would increase MVPA. In a new ... Pediatrics , researchers confirmed that time spent outdoors after ...
(Date:7/9/2014)... For the first time, researchers have access to detailed ... uses health care. A new study, called Our Health ... unique challenges faced by urban Aboriginal people in Canada ... , The findings, published today in BMJ Open ... and the general population. , Researchers interviewed 554 First ...
(Date:7/9/2014)... (PHILADELPHIA) Researchers at the Perelman School of Medicine ... Roswell Park Cancer Institute have received an $8 million ... the effects of photodynamic light therapy (PDT) in patients ... cancer that most often manifests itself in the lining ... exposure to asbestos. The grant will fund a clinical ...
(Date:7/9/2014)... types of cancer sends the protein factories in our ... uncontrolled growth, new research suggests. , Scientists at The ... responsible for ratcheting up activity of the endoplasmic reticulum ... blocks cancer cells need to keep growing. , A ... the flow of messages to the endoplasmic reticulum telling ...
(Date:7/9/2014)... cancer, researchers have uncovered mutations in a cell-signaling pathway ... knowledge may expand treatments for patients because drugs targeting ... are in clinical trials. , Reporting July 9 in ... (TCGA), including researchers at Washington University School of Medicine ... studied tumors from 230 patients with lung adenocarcinoma. , ...
Breaking Medicine News(10 mins):Health News:Go play outside! Outdoor time promotes physical activity in youth 2Health News:Urban Aboriginal people face unique health challenges 2Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2
... A new Institute of Medicine report specifies the types ... require before allowing tobacco companies to sell or advertise ... the health risks of tobacco use. While modified ... comprehensive strategy to lower tobacco-related death and disease in ...
... 10th and 12th-graders are at their lowest point since ... in 1975, according to this year,s survey results. However, ... of decline in teen smoking as well as continued ... hookahs, small cigars, smokeless tobacco), marijuana and prescription drugs. ...
... is available in German . Next ... have been announced: The Joint Committee of the Deutsche Forschungsgemeinschaft ... two women and nine men as winners of ... nominations committee from 131 nominations. Five of the award winners ...
... its ongoing efforts to ensure safe, effective and appropriate ... the ABIM Foundation and eight other medical specialty societies ... by physicians and patients to improve health outcomes, avoid ... The ACR will develop a list of ...
... a new mechanism that could potentially explain why the body,s ... shed light on the possible cause of immune resistance in ... low-cost drug used for more than a century to treat ... "This discovery may lead to new approaches for the treatment ...
... Queensland University of Technology (QUT) PhD student has developed ... the spread or return of breast cancer. , ... in the treatment of breast cancer there has been ... a PhD student at the Institute of Health and ...
Cached Medicine News:Health News:New report identifies research needed on 'modified risk' tobacco products 2Health News:New report identifies research needed on 'modified risk' tobacco products 3Health News:Cigarette and alcohol use at historic low among teens 2Health News:Cigarette and alcohol use at historic low among teens 3Health News:Cigarette and alcohol use at historic low among teens 4Health News:Leibniz Prize 2012 to honor 11 outstanding researchers 2Health News:Leibniz Prize 2012 to honor 11 outstanding researchers 3Health News:Leibniz Prize 2012 to honor 11 outstanding researchers 4Health News:Leibniz Prize 2012 to honor 11 outstanding researchers 5Health News:Leibniz Prize 2012 to honor 11 outstanding researchers 6Health News:Leibniz Prize 2012 to honor 11 outstanding researchers 7Health News:Leibniz Prize 2012 to honor 11 outstanding researchers 8Health News:Leibniz Prize 2012 to honor 11 outstanding researchers 9Health News:Leibniz Prize 2012 to honor 11 outstanding researchers 10Health News:Leibniz Prize 2012 to honor 11 outstanding researchers 11Health News:Leibniz Prize 2012 to honor 11 outstanding researchers 12Health News:ACR in Choosing Wisely campaign to promote wise use of resources among physicians and patients 2Health News:Heart drug may be effective for managing certain cancers: Queen's University study 2Health News:New test to indicate likely spread or recurrence of breast cancer 2
The incorporation of a reverse osmosis (RO) system and an ultrapure water system into a single stand-alone tower provides numerous benefits to the busy laboratory....
... systems produce ultrapure water from pre-treated water at ... to meet the basic needs of scientific laboratories. ... lamp (185 nm and 254 nm) to produce ... 5 ppb TOC when fed by Elix water). ...
... speed, stability and durability. Back-lighted Display. ... multiple units of measure, piece counting ... and GLP/GMP/ISO output including date and ... Built-in, motor-driven internal calibration mass for ...
... UniBloc weighing mechanism for speed, stability ... control, analog display modes, multiple units ... measure functions, auto print, and GLP/GMP/ISO ... from built-in clock. Built-in, motor-driven ...
Medicine Products: